Acurx Pharmaceuticals ACXP
NASDAQ ACXP
$1.15 +0.01 (+0.88%)
At close: Oct 21, 2026 · 4:00 PM EDT

Acurx Pharmaceuticals (ACXP) Return on Equity [ROE] (2025 - 2026)

Updated

Acurx Pharmaceuticals (ACXP) reported Return on Equity [ROE] of -98.99% for Q2 2026, up 241.24 percentage points from -340.23% a year earlier and up 23.11 percentage points from the prior quarter.

Analysis

Acurx Pharmaceuticals (ACXP) Return on Equity [ROE] (2025 - 2026) Analysis & Trends

For FY2025, Acurx Pharmaceuticals posted Return on Equity [ROE] of -270.80%, up 263.23 percentage points from FY2024.

  • By year, Return on Equity [ROE] came in at -534.03% in FY2024.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -122.11% (Q1 2026), -178.91% (Q4 2025) and -254.60% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 25.32%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 7.21%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 31.52%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 21.39%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 83.75%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -18.38%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 4.97%
10 Acurx Pharmaceuticals 4.86 Mn -28.61 Mn - -98.99%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -98.99%
Mar 31, 2026 -122.11%
Dec 31, 2025 -178.91%
Sep 30, 2025 -254.60%
Jun 30, 2025 -340.23%
Mar 31, 2025 -811.50%
API Access

Acurx Pharmaceuticals Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=ACXP&period=max&api_key=YOUR_API_KEY